Table 2.

Meta‐analysis of studies on adjuvant effects of bisphosphonates in breast cancer patients

Meta‐Analysis (by author)	Menopause status	Bisphosphonate	N of trials included	N	Breast cancer stage	Overall Recurrence	Distant Recurrence	Bone Recurrence	Mortality	Overall Survival Outcome
Valachis et al. 2010 36	Premenopausal, perimenopausal and postmenopausal	Pamidronate, Zoledronate, Clodronate, Risedronate	13	6886	Early	OR 0.84, 95% CI 0.60–1.18; P = 0.321	OR 0.90; 95% CI, 0.67–1.19; P = 0.453	OR 0.93, 95% CI 0.77–1.11; P = 0.413	0.71, 95% CI 0.48–1.04; P = 0.079
		Zoledronate	3–6	2925–4142		OR 0.68, 95% CI 0.48–0.95; P = 0.025		OR 0.66, 95% CI 0.38–1.15; P = 0.144	OR 0.64, 95% CI 0.39–1.06; P = 0.085
Valachis et al. 2013 38	Premenopausal, perimenopausal and postmenopausal	Zoledronate	15	6414	Early	HR 0.86, 95% CI 0.70–1.06; P = 0.15	HR 0.88, 95% CI 0.70–1.010; P = 0.27	HR 0.94, 95% CI 0.64–1.37; P = 0.74		HR 0.81, 95% CI 0.70–0.94
EBCTCG (Meta‐analysis) 8	Premenopausal, perimenopausal and postmenopausal	Pamidronate, Zoledronate, Clodronate, Risedronate Ibandronate	26	18 766	Early	RR 0.94, 95% CI 0.87–1.01; P = 0.08	RR 0.92, 95% CI 0.85–0.99; P = 0.03	RR 0.83, 95% CI 0.73–0.94; P = 0.004	RR 0.91, 95% CI 0.83–0.99; P = 0.04
	Postmenopausal			11 767	Early	RR 0.86, 95% CI 0.78–0.94; P = 0.002	RR 0.82, 95% CI 0.74–0.92; P = 0.0003	RR 0.72, 95% CI 0.60–0.86; P = 0.0002	RR 0.82, 95% CI 0.73–0.93; P = 0.002
O'Carrigan et al. 2017 39	Premenopausal, perimenopausal and postmenopausal	Zoledronate, Clodronate, Ibandronate, Pamidronate	11–7	15 005–12 578	Early	RR 0.94 (95% CI 0.87–1.02; P = 0.13)		RR 0.86, 95% CI 0.75–0.99; P = 0.03
			9	13 949	Early					HR 0.91, 95% CI 0.83–0.99; P = 0.04
	Postmenopausal		4–7	6048–8314	Early	HR 0.82, 95% CI 0.74–0.91; P = 0.001				HR 0.77, 95% CI 0.66–0.90; P = 0.001
	Premenopausal		2	3501	Early					HR 1.03, 95% CI 0.86–1.22; P = 0.78